Candriam SCA’s Akoya BioSciences AKYA Stock Holding History

Candriam SCA’s Portfolio AKYA Stock Details AKYA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-276,300	Closed	-$2.04M	–	659
2023 Q2	$2.04M	Buy	276,300 +20,000	+8%	+$134K	0.01%	491
2023 Q1	$1.93M	Buy	256,300 +94,000	+58%	+$982K	0.01%	584
2022 Q4	$1.55M	Sell	162,300 -9,000	-5%	-$111K	0.01%	621
2022 Q3	$2.01M	Buy	171,300 +12,000	+8%	+$158K	0.01%	583
2022 Q2	$2.05M	Hold	159,300	–	–	0.02%	503
2022 Q1	$1.75M	Buy	159,300 +109,000	+217%	+$1.26M	0.01%	572
2021 Q4	$770K	Buy	50,300 +8,000	+19%	+$105K	﹤0.01%	708
2021 Q3	$590K	Buy	+42,300	New	+$707K	﹤0.01%	774

Other funds holding AKYA

BWLSA

Blue Water Life Science Advisors Larkspur, California $125M AUM 91.82% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KLC

Kent Lake Capital Reno, Nevada $222M AUM 18.04% 1-Year Est. Return

BOTOTLSJU

Board of Trustees of The Leland Stanford Junior University Redwood City, California $849M AUM 55.45% 1-Year Est. Return

UIC

Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

PHP

Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return

SVB Wealth Boston, Massachusetts $1.59B AUM 24.57% 1-Year Est. Return

Candriam SCA's AKYA Position: Q3 2023 in Review

Candriam SCA sold out of Akoya BioSciences (AKYA) in Q3 2023, closing a stake of 276,300 shares — an estimated $2.04M sold.

Candriam SCA first reported a position in AKYA in Q3 2021 and held it in 8 quarters. The position peaked at $2.05M in Q2 2022. 62 funds tracked by Wall St. Rank hold AKYA as of Q3 2023.

Candriam SCA reported no remaining Akoya BioSciences position as of Q3 2023 after selling out during the quarter.
Candriam SCA sold 276,300 Akoya BioSciences shares in Q3 2023, an estimated $2.04M.
Candriam SCA first reported a position in Akoya BioSciences in Q3 2021 and held it in 8 quarters.
Candriam SCA's Akoya BioSciences position peaked at $2.05M in Q2 2022.
62 funds tracked by Wall St. Rank held Akoya BioSciences as of Q3 2023.

Based on Candriam SCA's 13F filing for Q3 2023, filed 13 Nov 2023.